| Name | Zosuquidar |
| Description | Zosuquidar (RS 33295-198) is a potent P-glycoprotein inhibitor with antitumor activity, inhibits tumor growth, significantly inhibits PD-L1 expression by triggering its autophagic degradation, and is used in the study of acute myeloid leukemia. |
| In vitro | Zosuquidar (0.3 μM, treated for 48 hours) enhances the cytotoxic effect of DNR (P-glycoprotein substrate) in P-glycoprotein-active cell lines. [2]
Zosuquidar (5-16 μM, treated for 72 hours) alone exhibited strong cytotoxicity in drug-sensitive cell lines and multidrug resistant (MDR) cell lines. [1] |
| In vivo | Intraperitoneal injection of 30, 10, 3, or 1 mg/kg Zosuquidar once daily for 5 days significantly prolonged subject survival. [1]
Intraperitoneal injection of 30 mg/kg Zosuquidar once daily for 5 days observed a significant potentiation when combined with adriamycin (Doxorubicin). [1] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (9.48 mM), Sonication is recommended.
DMSO : 80 mg/mL (151.63 mM), Sonication is recommended.
|
| Keywords | Zosuquidar |
| Inhibitors Related | Atazanavir | Trifluoperazine dihydrochloride | Verapamil hydrochloride | Glibenclamide | Encequidar mesylate | Polyoxyethylene stearate | 1-piperoylpiperidine | Tariquidar | Cinchonine | Bifendate | Atazanavir sulfate | Bisdemethoxycurcumin |
| Related Compound Libraries | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
